Eikon Therapeutics, a protein-dynamics drug developer founded by former Merck executives, signaled plans to go public and to use proceeds to fund a clutch of oncology and neuroscience programs. The company has raised over $1 billion in private funding and reported four programs in human testing, including EIK1001 (TLR-targeting) with a Phase 2/3 melanoma study and mid-stage lung cancer trial. Eikon’s filing and public messaging highlight a platform built around high-resolution protein motion technologies and deal-driven pipeline expansion. The company expects interim clinical readouts later this year, and its IPO would follow a renewed market appetite for high-profile biotech offerings.